S100A12 Protein Levels in Juvenile Idiopathic Arthritis (JIA): a Systematic Review and Meta-Analysis.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2025-05-01 DOI:10.7754/Clin.Lab.2024.241041

Tarun K Sharma, Somya Saxena, Pooja Arora, Anil K Sharma

{"title":"S100A12 Protein Levels in Juvenile Idiopathic Arthritis (JIA): a Systematic Review and Meta-Analysis.","authors":"Tarun K Sharma, Somya Saxena, Pooja Arora, Anil K Sharma","doi":"10.7754/Clin.Lab.2024.241041","DOIUrl":null,"url":null,"abstract":"Background: Juvenile idiopathic arthritis (JIA) is a childhood inflammatory disease, which is a common cause of disability among the younger population. S100A12 protein level is found to be associated with the patients of JIA; though, the findings on this are inconsistent. Therefore, we conducted a systematic review and meta-analysis to assess the association of S100A12 protein levels with juvenile idiopathic arthritis.Methods: Relevant published studies up to December 2022 were identified by systematic literature searching on Embase, PubMed/Medline, Web of Science, and Scopus for exploring the association of S100A12 protein levels with juvenile idiopathic arthritis (JIA). The data analysis was performed using the R-4.4.0 software.Results: We included 9 eligible studies on serum S100A12 protein levels in JIA and healthy controls, which encompassed 518 JIA patients and 345 healthy control subjects. The pooled analysis revealed that the serum S100A12 protein levels increased significantly (summary SMD = 2.18, 95% CI: 0.63 - 3.74, overall effect size z = 2.76, p < 0.01) in JIA subjects in comparison to healthy control subjects. The pooled results of subgroup analysis for the Europe and Asia group' studies were SMD = 2.75, (95% CI [-0.09 to 5.58]; p < 0.01) and SMD = 1.53, (95% CI [-0.27 to 3.32]; p < 0.01), respectively, and both groups based on geographical regions exhibited significant hetero-geneity (I2 = 97.0% and I2 = 98.0% respectively, p < 0.01). Similarly, in cohort and case-control study groups, the results were SMD = 1.70, (95% CI [0.36 to 3.04]; p < 0.01) and SMD = 1.29, (95% CI [0.03 to 2.55]; p < 0.01), respectively, and both groups based on study type also exhibited significant heterogeneity (I2 = 97.0% and I2 = 96.0%, respectively, p < 0.01).Conclusions: This meta-analysis suggests that the S100A12 protein serum concentrations of JIA were significantly higher than those of healthy controls, which suggests that serum S100A12 protein could be a potential biomarker for JIA.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 5","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.241041","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Juvenile idiopathic arthritis (JIA) is a childhood inflammatory disease, which is a common cause of disability among the younger population. S100A12 protein level is found to be associated with the patients of JIA; though, the findings on this are inconsistent. Therefore, we conducted a systematic review and meta-analysis to assess the association of S100A12 protein levels with juvenile idiopathic arthritis.

Methods: Relevant published studies up to December 2022 were identified by systematic literature searching on Embase, PubMed/Medline, Web of Science, and Scopus for exploring the association of S100A12 protein levels with juvenile idiopathic arthritis (JIA). The data analysis was performed using the R-4.4.0 software.

Results: We included 9 eligible studies on serum S100A12 protein levels in JIA and healthy controls, which encompassed 518 JIA patients and 345 healthy control subjects. The pooled analysis revealed that the serum S100A12 protein levels increased significantly (summary SMD = 2.18, 95% CI: 0.63 - 3.74, overall effect size z = 2.76, p < 0.01) in JIA subjects in comparison to healthy control subjects. The pooled results of subgroup analysis for the Europe and Asia group' studies were SMD = 2.75, (95% CI [-0.09 to 5.58]; p < 0.01) and SMD = 1.53, (95% CI [-0.27 to 3.32]; p < 0.01), respectively, and both groups based on geographical regions exhibited significant hetero-geneity (I2 = 97.0% and I2 = 98.0% respectively, p < 0.01). Similarly, in cohort and case-control study groups, the results were SMD = 1.70, (95% CI [0.36 to 3.04]; p < 0.01) and SMD = 1.29, (95% CI [0.03 to 2.55]; p < 0.01), respectively, and both groups based on study type also exhibited significant heterogeneity (I2 = 97.0% and I2 = 96.0%, respectively, p < 0.01).

Conclusions: This meta-analysis suggests that the S100A12 protein serum concentrations of JIA were significantly higher than those of healthy controls, which suggests that serum S100A12 protein could be a potential biomarker for JIA.

查看原文本刊更多论文

青少年特发性关节炎（JIA）的S100A12蛋白水平：一项系统综述和荟萃分析

背景：青少年特发性关节炎（JIA）是一种儿童期炎症性疾病，是青少年致残的常见原因。发现S100A12蛋白水平与JIA患者相关；然而，这方面的研究结果并不一致。因此，我们进行了系统回顾和荟萃分析，以评估S100A12蛋白水平与幼年特发性关节炎的关系。方法：通过Embase、PubMed/Medline、Web of Science、Scopus等数据库系统检索截至2022年12月发表的相关研究，探讨S100A12蛋白水平与幼年特发性关节炎（JIA）的相关性。采用R-4.4.0软件进行数据分析。结果：我们纳入了9项符合条件的JIA和健康对照血清S100A12蛋白水平研究，其中包括518名JIA患者和345名健康对照。合并分析显示，与健康对照组相比，JIA组血清S100A12蛋白水平显著升高（总SMD = 2.18, 95% CI: 0.63 ~ 3.74，总效应大小z = 2.76, p < 0.01）。欧洲和亚洲组研究的亚组分析汇总结果为SMD = 2.75, (95% CI [-0.09 ~ 5.58]；p < 0.01), SMD = 1.53, (95% CI [-0.27 ~ 3.32]；p < 0.01)，且地理区域组间异质性显著（I2 = 97.0%, I2 = 98.0%, p < 0.01）。同样，在队列和病例对照研究组中，结果SMD = 1.70, (95% CI [0.36 ~ 3.04]；p < 0.01), SMD = 1.29, (95% CI [0.03 ~ 2.55]；p < 0.01)，且基于研究类型的两组均存在显著异质性（I2 = 97.0%, I2 = 96.0%, p < 0.01）。结论：本荟萃分析提示JIA患者血清S100A12蛋白浓度显著高于健康对照组，提示血清S100A12蛋白可能是JIA的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.